What HRSA’s Revised 340B Rebate Pilot Means for Contract Pharmacies, Health Systems and FQHCs

On October 1, HRSA disclosed that ten manufacturers had received approval to participate in the revised 340B Rebate Model Pilot Program. The approved plans cover 21 drugs, and the program is scheduled to begin January 1, 2027.

The HRSA pilot page now lists the participating manufacturers, covered drugs, technology platforms and implementation requirements. The pilot will use rebates instead of upfront discounts for a limited group of drugs connected to the Medicare Drug Price Negotiation Program.

That change matters to covered entities, health systems, federally qualified health centers and contract pharmacies because it affects purchasing, claims data, reimbursement timing and compliance responsibilities.

This is a second attempt

The revised pilot follows an earlier effort that was scheduled to begin January 1, 2026.

Covered-entity stakeholders, including the American Hospital Association, challenged the original program under the Administrative Procedure Act. The U.S. District Court for the District of Maine issued a nationwide preliminary injunction on December 29, 2025. The First Circuit declined to stay that order, HHS withdrew the original pilot, and the Maine court later vacated and remanded the original notices and manufacturer approvals.

HRSA’s revised program is therefore a new and contested approach, not a simple restart. On October 1, the AHA said it was considering all available options to stop the revised pilot. That statement does not establish that a new lawsuit has been filed, though further litigation and congressional action remain possible.

The D.C. Circuit’s decision in Novartis Pharmaceuticals Corp. v. Kennedy confirms that Section 340B permits rebate models and that manufacturers may not implement them without HHS approval. The court did not decide that every possible rebate model would comply with the statute.

The pilot is narrower than the program as a whole

The pilot does not apply to every 340B drug.

HRSA limits it to the NDC-11s of drugs appearing on the CMS Medicare Drug Price Negotiation Selected Drug Lists for initial price applicability years 2026 and 2027, and only during the applicable price periods.

HRSA estimated that the eligible universe represented less than 5.5% of total 340B sales. The final approved plans cover 21 drugs, so the share actually affected by the pilot may be smaller than the initial estimate. The remaining 94.5% of 340B sales is expected to remain under the upfront-discount model in 2027.

The broader $100 billion figure describes total 340B purchases, not the size of the rebate pilot. Program-wide specialty-pharmacy and covered-entity statistics should not be presented as though they describe the pilot’s reach.

What changes for covered entities

For affected drugs, covered entities may need to purchase through existing distribution channels at the wholesale acquisition cost and then submit claims data to receive the 340B rebate.

The approved plans must provide:

• At least 90 calendar days’ notice before implementation.

• At least 45 calendar days from the date of dispense to submit required data.

• Payment of the rebate, or a documented denial, within 10 calendar days after a completed submission.

• A 15-calendar-day transition grace period for up to two unreplenished accumulated packages dispensed before the effective date, provided the rebate request is still submitted within the 45-day period.

The 90-day notice period should be underway now for plans intended to take effect January 1, 2027. Covered entities should confirm when each manufacturer delivered its notice and whether the notice explains the required registration and data-submission process.

The approved plans also require manufacturers to identify the technology platform used for submissions, pay the platform’s costs, provide claim-status information and document the reasons for denied rebates.

The ten-day payment clock begins only after a completed submission. If a submission is returned as incomplete, the clock restarts when the missing information is provided. That makes the process for correcting incomplete claims an important operational issue.

The cash-flow issue needs a balanced assessment

The rebate model may require some entities to order selected drugs at WAC rather than receiving the 340B discount at the point of purchase.

HRSA expects the cash-flow effect to be limited because, in most cases, payment to wholesalers should occur after the manufacturer rebate is received. The pilot also uses unit-level rebate processing and includes transition accommodations intended to reduce inventory disruption.

That expectation may not hold equally for every entity. Cash-flow exposure will depend on wholesaler payment terms, claim-submission speed, incomplete data, denials, credit arrangements and the entity’s ability to reconcile claims promptly.

Covered entities should model the timing by drug, manufacturer, dispensing channel and contract-pharmacy arrangement rather than assume that the financial effect will be either insignificant or severe.

What executives should do now

Health systems, FQHCs and contract pharmacies should:

1. Identify the affected NDC-11s and determine which dispensing channels are involved.

2. Assign responsibility for claim submission, reconciliation, corrections and denial appeals.

3. Confirm that pharmacy, wholesaler, TPA and 340B software systems can produce the required data.

4. Test the 45-day submission window and ten-day payment timetable.

5. Review wholesaler credit terms and model exposure during delayed, incomplete or denied claims.

6. Confirm whether the manufacturer’s 90-day notice has been delivered and whether platform registration is required.

7. Track the 15-day transition rule for unreplenished inventory.

8. Document how the new process affects patient access, inventory and reimbursement.

How Lanton, Lanton & Sosa Law PLLC can help

Lanton, Lanton & Sosa Law PLLC advises healthcare organizations, pharmacies and life-sciences companies on 340B, reimbursement, regulatory compliance and government affairs.

For this pilot, that work may include reviewing manufacturer and contract-pharmacy arrangements, assigning legal and operational responsibilities, evaluating claims and data requirements, assessing denial and dispute procedures, modeling reimbursement exposure and preparing for agency or manufacturer inquiries.

The revised pilot is limited in scope, yet it introduces a new payment and data process into a program that serves thousands of covered entities. The entities that prepare early will be better positioned to identify errors, protect reimbursement and maintain access for patients.

Sources

• HRSA 340B Rebate Model Pilot Program

• Federal Register notice, 91 FR 48883

• Novartis Pharmaceuticals Corp. v. Kennedy, D.C. Circuit

• CMS Medicare Drug Price Negotiation Program

340B Rebates: Who Bears the Cost of Changing How the Program Works?

Why the 340B Program Matters

Congress established the 340B Drug Pricing Program in 1992 to help eligible healthcare organizations stretch scarce resources and serve patients. Under the program, manufacturers participating in Medicaid and Medicare Part B agree to provide qualifying outpatient drugs at or below a statutory ceiling price to eligible hospitals, health centers and other providers known as covered entities. The program has generally delivered that price through an upfront purchasing discount. [1]

That purchasing arrangement is now embedded in many organizations’ pharmacy operations. Covered entities use 340B savings in different ways, which can include supporting medication access, specialty services and care for patients who may face barriers to treatment. The program is also operationally complex: hospitals and clinics may use in-house or contract pharmacies, wholesalers, inventory replenishment systems and third-party administrators to determine which transactions qualify.

The 340B statute prohibits diversion of discounted drugs to ineligible patients and duplicate discounts involving Medicaid rebates. Determining which transactions qualify and identifying overlapping price concessions have become persistent administrative questions as the program and pharmaceutical distribution arrangements have grown. [1]

HRSA’s revised rebate pilot is designed to test whether a rebate-based approach addresses these administrative questions more effectively than the existing upfront-discount model. It applies to a limited set of drugs, rather than changing 340B purchasing across the program. [1, pp. 48,894–48,896]

Why Manufacturers Are Interested in a Rebate Model

Manufacturers have argued that an upfront discount can make it difficult to verify the specific transaction that ultimately qualifies for 340B pricing. They have sought greater visibility into claims data to identify duplicate discounts, evaluate eligibility and reconcile overlapping requirements across federal drug-pricing programs. For selected Medicare-negotiated drugs, the pilot also addresses potential overlap between 340B discounts and Medicare Maximum Fair Price (MFP) discounts; these price concessions are not cumulative. [1, pp. 48,884–48,886]

Supporters of rebate-based arrangements contend that linking payment to a validated dispensing or administration record could improve claims-level transparency and reduce the need to identify problems only through retrospective audits. They also argue that covered entities and their administrators already collect much of the information that would be used for reporting. [1]

Those arguments do not resolve every implementation issue. More transaction data raises questions about the information manufacturers may receive, permitted uses of that information, privacy, platform governance and the cost of producing and verifying claims. Whether the anticipated benefits materialize is part of what the pilot is designed to examine.

What the Revised Pilot Would Actually Change

In July 2026, the Health Resources and Services Administration announced a revised, voluntary pathway for qualifying manufacturers to provide 340B pricing through rebates instead of upfront discounts. The pilot is limited to selected drugs in the Medicare Drug Price Negotiation Program with initial price applicability years 2026 and 2027, during their applicable pricing periods. HRSA estimates that the included products represent less than 5.5% of total 340B sales, based on 2025 data. The rest of the program would continue using upfront discounts in 2027. [1, pp. 48,893–48,894; 2]

For an approved participating product, the covered entity would order through existing distribution channels at wholesale acquisition cost (WAC). Following an eligible dispense or administration, it would submit specified transaction information. The rebate would equal WAC minus the applicable 340B ceiling price on the day of dispense and would be paid at the unit level. This means the financial benefit arrives through a separate transaction rather than being reflected in the initial acquisition price. [1]

The revised framework includes several operational safeguards. Manufacturers must fund the required submission platforms and provide technical assistance. Their approved plans must allow at least 90 calendar days’ notice before implementation, and covered entities must have at least 45 calendar days after dispensing to submit data, with specified allowances for exceptions. Manufacturers must pay the rebate or issue a documented denial within ten calendar days after receiving a complete submission. An incomplete submission can restart that payment clock when the missing information is supplied. [1]

The pilot is scheduled to begin January 1, 2027, for manufacturers whose rebate plans receive HHS approval. It does not change purchasing for products outside its limited scope. [1]

Why Hospitals Are Concerned

Hospitals and health systems have raised concerns about the effect of moving from a known upfront acquisition discount to a later rebate. One issue is liquidity: an organization may need to purchase a high-cost drug at WAC, hold it in inventory, dispense or administer it, submit transaction information and wait for a validated rebate. Even a ten-day payment requirement begins after a complete submission, not necessarily on the purchase date. [1]

Covered entities have also pointed to potential administrative costs, including staff training, system changes, reconciliation, disputed transactions and changes to wholesaler credit arrangements. Their concern is not limited to whether a rebate ultimately arrives. For some hospitals, uncertainty or new financing costs could affect resources used to maintain services, including medication access and other programs serving vulnerable patients. Those effects would differ by facility and cannot be inferred from a uniform estimate. [1]

HRSA takes a different view of the likely financial impact. It expects the ten-day deadline, unit-level rebates and existing wholesaler payment windows to allow many organizations to receive rebates before their wholesaler invoices become payable. The agency also expects existing pharmacy systems and third-party administrators to absorb much of the additional work, although it acknowledges that some covered entities may need new resources. [1]

The two positions turn in part on actual purchasing arrangements. A rebate paid before the relevant wholesaler invoice is due may create little additional financing expense. A different experience is possible when inventory moves slowly, submissions are incomplete, credit terms are tight or reconciliation is difficult. The pilot’s practical effects will need to be assessed across different provider types and purchasing models.

Who Bears the Financial and Administrative Costs?

The answer is not a single stakeholder. The revised pilot assigns some obligations explicitly, while other costs depend on how organizations purchase drugs, operate their systems and contract with service providers.

Participant

Responsibility or potential exposure

Manufacturers

Fund the required data-submission platforms; validate eligible submissions; pay or document denials on time; provide technical assistance and required reporting.

Covered entities

Manage purchasing and eligible-claim submissions; reconcile rebates; potentially absorb internal system, training, staffing and working-capital costs.

Third-party administrators and technology vendors

Perform data extraction, submission, monitoring and reconciliation under their contracts; compensation and liability for additional services depend on those agreements.

Wholesalers

Existing invoice, credit and payment terms influence whether the covered entity receives its rebate before the acquisition invoice is due.

HRSA estimates an average annual claims-reporting cost of approximately $34,320 per covered entity under its information-collection analysis, with actual costs varying by entity type. This is an average regulatory estimate, not a prediction of what any particular hospital will spend. Manufacturers are required to fund the submission platforms, but that does not necessarily cover all costs of a covered entity’s internal preparation, integration, monitoring or dispute management. [1, pp. 48,892–48,894]

The contractual questions follow naturally. Who corrects an incomplete claim? Who tracks the restarted payment deadline? Which party carries the cost of an error, additional integration work or a reconciliation backlog? Existing arrangements may address some of these questions, but organizations should not assume every agreement was written for a rebate workflow.

Contract Pharmacy Considerations

Contract pharmacy arrangements add another operational layer. A covered entity may rely on a retail or specialty pharmacy partner to dispense eligible drugs and on an administrator to determine eligibility and manage replenishment. The covered entity retains responsibility for 340B compliance, even when other organizations perform parts of the workflow. HRSA’s notice includes contract pharmacy arrangements in its discussion of the pilot and acknowledges the complexity of coordinating claims and transaction data across these relationships. [1, pp. 48,887–48,888, 48,893–48,894]

Depending on the arrangement, the parties may need to clarify who gathers and submits transaction data, corrects incomplete submissions, tracks rebate payments and resolves discrepancies. Existing contract pharmacy and administrator agreements should be reviewed for data-sharing permissions, confidentiality, reconciliation duties, payment allocation and dispute procedures. The extent of any changes will depend on how the covered entity already operates and the terms of its contracts.

Data, Denials and the Limits of Verification

The revised pilot requires defined data elements, appropriate safeguards for personal and health information, reconciliation reporting and documented reasons for rebate denials. Under the notice, manufacturers may not deny a rebate based on covered-entity eligibility concerns, diversion, Medicaid duplicate-discount concerns or perceived insufficient WAC purchases. Those issues must instead be raised with HRSA or pursued through the program’s established audit and dispute mechanisms. The notice permits certain documented denials, including when a rebate would duplicate an applicable Medicare Maximum Fair Price discount or when another covered entity has already received a 340B rebate on the same claim. Because the pilot concerns selected Medicare-negotiated drugs during their price applicability periods, MFP nonduplication is part of the pilot’s design. [1, p. 48,903]

These provisions limit the grounds for denial without eliminating the need for claim validation and dispute management. Covered entities and their service providers should establish who reviews rejected submissions, corrects incomplete data, preserves records, monitors payment deadlines and escalates recurring problems. Relevant contracts should address data use, privacy, audit rights, service standards and responsibility for errors.

The Legal and Medicare Payment Context

The revised pilot follows an earlier program scheduled to begin in January 2026. On December 29, 2025, a federal district court preliminarily enjoined the earlier program, finding that HRSA had likely failed to adequately consider hospitals’ reliance on upfront discounts. HRSA subsequently withdrew that program. On February 10, 2026, the district court granted the parties’ joint motion for vacatur and remand, vacating the earlier notices and manufacturer approvals. Neither order was a final ruling on the lawfulness of rebate mechanisms generally; the revised 2026 pilot is a distinct agency action. [3, 4]

In a separate dispute, the D.C. Circuit held in July 2026 that Section 340B permits rebate mechanisms when the Secretary of Health and Human Services affirmatively provides for them, but manufacturers may not impose such models unilaterally without Secretarial approval. The court did not decide whether any particular proposed arrangement should receive approval or resolve possible procedural challenges to the revised pilot. [5]

A separate proposal could also affect hospital financial planning in 2027. In its CY 2027 Hospital Outpatient Prospective Payment System proposed rule, CMS proposed paying most separately payable 340B-acquired drugs at average sales price minus 33.4%, rather than the generally applicable ASP plus 6% rate. CMS estimated lower Medicare drug and beneficiary payments, with a corresponding budget-neutral increase in other outpatient payments. As of September 2026, this remains a proposal, not a finalized payment change or an additional requirement of the HRSA rebate pilot. Financial effects would vary across hospitals. [6]

Hospitals evaluating the pilot may therefore want to model the acquisition and rebate process separately from potential Medicare payment changes, then consider their combined impact if both policies ultimately take effect.

Five Questions Organizations Should Ask

Financial exposure: For affected drugs, when do we purchase, dispense, submit claims, receive rebates and pay our wholesalers?

Operational readiness: Can existing pharmacy, claims and accounting systems support the required reporting and reconciliation processes?

Contracting: Do vendor and administrator agreements clearly assign responsibility for errors, incomplete submissions, payment tracking, disputes and additional service costs?

Data and compliance: Are approved data uses, privacy safeguards, reporting obligations and denial-review procedures clear?

Policy status: Who will track HRSA guidance, relevant litigation and the separate CMS payment proposal?

What the Pilot May Tell Us

The pilot applies to a small share of total 340B sales, but it offers a defined setting in which to measure how a claims-based rebate process works. Relevant evidence will include actual payment timing, administrative expense, rejection and dispute rates, platform performance and the differences among covered entities with distinct purchasing and technology arrangements. A broader shift is not predetermined by this limited pilot.

The practical question is whether participating organizations can deliver the required data, obtain accurate and timely rebates, allocate operational responsibilities and understand the costs they incur. Those results, rather than assumptions about how either model should perform, will provide a more useful basis for evaluating the program.

How Lanton, Lanton & Sosa Law Can Help

Lanton, Lanton & Sosa Law advises healthcare and life sciences organizations on pharmaceutical reimbursement, regulatory compliance, commercial contracting and pharmacy operations. As 340B requirements evolve, we help clients evaluate the rules affecting their businesses, review agreements and address implementation and compliance questions.

Organizations reviewing new rebate arrangements, technology or administrator contracts, or changes to purchasing and reimbursement can contact the firm to discuss their specific circumstances: www.lantonlaw.com/contact.

This publication is provided for general informational purposes only and does not constitute legal advice. Regulatory guidance, litigation and Medicare payment policies may change.

Selected Sources

[1] Health Resources and Services Administration, Notice Regarding 340B Rebate Model Pilot Program, 91 Fed. Reg. 48,883–48,903 (Aug. 3, 2026), especially 48,884–48,886 (statutory framework and MFP), 48,892–48,894 (cost analysis and pilot scope), and 48,902–48,903 (plan requirements and denials). https://www.govinfo.gov/content/pkg/FR-2026-08-03/pdf/2026-15633.pdf

[2] HRSA, Revised 340B Rebate Model Pilot Program announcement (July 31, 2026). https://www.hrsa.gov/about/news/press-releases/revised-340b-program-2026

[3] American Hospital Association v. Kennedy, 820 F. Supp. 3d 30, 44 (D. Me. 2025) (preliminary injunction concerning the earlier pilot, Dec. 29, 2025). https://docs.justia.com/cases/federal/district-courts/maine/medce/2%3A2025cv00600/69459/90

[4] American Hospital Association v. Kennedy, Order Granting Joint Motion for Vacatur and Remand (D. Me. Feb. 10, 2026). https://docs.justia.com/cases/federal/district-courts/maine/medce/2%3A2025cv00600/69459/115

[5] Novartis Pharmaceuticals Corp. v. Kennedy, No. 25-5177 (D.C. Cir. July 21, 2026) (approval required before manufacturers may implement rebate arrangements unilaterally). https://law.justia.com/cases/federal/appellate-courts/cadc/25-5177/25-5177-2026-07-21.html

[6] CMS, CY 2027 Hospital Outpatient Prospective Payment System Proposed Rule Fact Sheet (July 2, 2026). https://www.cms.gov/newsroom/fact-sheets/calendar-year-2027-hospital-outpatient-prospective-payment-system-opps-ambulatory-surgical-center

FDA Extends Certain DSCSA Exemptions for Small Pharmacies: What the Additional Year Means

The Food and Drug Administration has given qualifying small pharmacies another year to implement certain enhanced drug distribution security requirements under the Drug Supply Chain Security Act.

On August 6, 2026, FDA announced that small dispensers, along with their trading partners where applicable, will receive exemptions from certain requirements through November 27, 2027. The prior exemption period was scheduled to end on November 27, 2026.

For independent and community pharmacies still working through technology, data exchange, staffing, and trading partner challenges, the additional year is meaningful. It is not, however, a suspension of DSCSA compliance.

The exemption applies only to specific enhanced drug distribution security requirements. Other DSCSA responsibilities remain in effect, and FDA is continuing to urge small dispensers to make progress toward full implementation.

Which Pharmacies Qualify?

For purposes of the new exemptions, FDA considers a dispenser to be a small dispenser if the company that owns the dispenser has 25 or fewer full time employees who are licensed pharmacists or qualified pharmacy technicians as of November 27, 2026.

This means the analysis is based on the company that owns the pharmacy, not necessarily the employee count at one individual pharmacy location. Organizations operating multiple locations should therefore examine their ownership structure and total number of qualifying employees before concluding that the exemption applies.

Qualifying small dispensers do not need to submit an application or notify FDA to use the exemption. A pharmacy should still document its eligibility internally and be prepared to explain the basis for relying on it.

What Has Been Extended?

The exemptions apply to certain enhanced security requirements involving interoperable, electronic, package level product tracing.

During the exemption period, qualifying small dispensers and, where applicable, their trading partners may continue using existing methods for certain activities that would otherwise require fully interoperable electronic systems. These include aspects of:

• Exchanging transaction information and transaction statements electronically

• Including package level product identifiers in transaction information

• Conducting product verification at the package level

• Responding to government requests for transaction information during recalls or investigations

• Gathering transaction information back through the supply chain

• Processing certain saleable returns

The exemption also covers specific product identifier verification requirements when a qualifying pharmacy investigates suspect or illegitimate products. It does not eliminate the pharmacy’s other investigation and verification responsibilities.

What the Exemption Does Not Cover

The extension should not be treated as a general waiver from DSCSA.

Pharmacies must still purchase prescription drugs from authorized trading partners. They must maintain applicable transaction records, identify and investigate suspect products, quarantine products when appropriate, and notify FDA and relevant trading partners when illegitimate products are discovered.

Pharmacies must also maintain policies and procedures that allow employees to recognize and respond to products that may be counterfeit, diverted, stolen, adulterated, or otherwise unfit for distribution.

The additional year changes the timeline for certain enhanced electronic requirements. It does not erase the underlying obligation to protect the integrity of the drug supply chain.

Why FDA Granted More Time

FDA granted the additional exemption while an independent assessment examines whether small dispensers can feasibly implement interoperable, electronic tracing at the package level.

That assessment will evaluate the technology and software available to small pharmacies, including whether existing systems are accessible, functional, and economically feasible. FDA is encouraging small dispensers to complete its assessment survey by September 22, 2026. A small dispenser may designate another organization, such as a consultant, to complete the survey on its behalf.

The survey gives independent pharmacies an opportunity to document the practical difficulties they encounter, including system costs, integration problems, staffing limitations, data quality issues, and dependencies on wholesalers or technology vendors.

How Pharmacies Should Use the Additional Year

The safest approach is to treat the extension as an implementation period, not a waiting period.

A pharmacy relying on the exemption should first document why it qualifies. That documentation should identify the ownership entity, the relevant employee count, and the methodology used to determine which employees are included.

The pharmacy should then evaluate its current DSCSA capabilities. This includes confirming whether it can receive and retrieve transaction information, identify its authorized trading partners, investigate suspect products, quarantine inventory, respond to information requests, and preserve the required records.

Pharmacies should also speak with their wholesalers, buying groups, and technology providers. A pharmacy may qualify for an exemption while one or more of its trading partners operate under different requirements. Understanding how each party will transmit, receive, store, and retrieve information can help prevent purchasing disruptions and inventory delays.

Written policies should reflect what the pharmacy is actually doing today. Employees responsible for purchasing, receiving, returns, inventory management, and product investigations should understand those procedures and know when a problem must be escalated.

Finally, pharmacies should keep records of their implementation efforts. Contracts, vendor communications, training records, system testing, written procedures, corrective actions, and internal assessments can help demonstrate that the pharmacy used the exemption period responsibly.

The Legal and Operational Risk Has Not Disappeared

DSCSA compliance is not solely a technology project. It involves vendor contracts, licensing, purchasing controls, record retention, employee training, product investigations, and relationships with trading partners.

A pharmacy that waits until the exemption is about to expire may discover that its software cannot communicate effectively with a wholesaler, its transaction data cannot be retrieved promptly, or its written policies no longer reflect its operations. Those problems can affect more than regulatory compliance. They can interrupt purchasing, delay returns, create audit exposure, and ultimately affect patient access.

FDA’s extension gives qualifying small pharmacies valuable time to address those risks. The best use of that time is to build a compliance program that is both operationally workable and legally defensible.

Lanton, Lanton & Sosa Law PLLC advises pharmacies, healthcare organizations, and other regulated businesses on compliance, contracting, audits, licensing, reimbursement, and operational risk. Organizations evaluating the DSCSA exemption should assess both their eligibility and the steps necessary to reach full compliance before the exemption ends.

This article is provided for general informational purposes and does not constitute legal advice.

Buying or Selling a Healthcare Practice Is Not Just a Regular Business Transaction

Buying or selling a healthcare practice can look simple from the outside. There is a buyer, a seller, a purchase price, and a set of documents that need to be signed. In healthcare, it is rarely that simple.

A medical practice, pharmacy, therapy practice, dental office, med spa, or other healthcare business is not just a collection of patients, equipment, contracts, leases, and revenue. It operates inside a regulated environment. That means the transaction has to account for issues that do not always show up in a basic business sale.

Licensure, payer contracts, patient records all matter. Employee obligations, referral relationships, corporate structure, privacy rules, billing history, and compliance risk matter too. Any one of those issues can affect the value of the practice and the ability of the buyer to keep the business operating after closing.

That is where many healthcare transactions become more complicated than expected.

A buyer may believe they are purchasing a stable book of business, only to find out that certain payer contracts cannot be assigned. A seller may assume the transition will be straightforward, only to discover that licensing timelines, lease restrictions, or patient notice requirements slow the deal down. A lender or investor may focus on revenue, while missing the regulatory issues that make that revenue harder to preserve.

The structure of the deal matters too.

An asset purchase and an equity purchase can create very different legal and operational consequences. The parties need to know whether professional licenses are changing, whether the seller will stay involved after closing, whether key employees need new agreements, whether the lease can be assigned, and whether the buyer can continue billing under the same contracts.

These are not issues to save for the end of the transaction. They should be part of the conversation before the parties get too far down the road on price, timing, and closing expectations.

For sellers, preparation can make the deal much cleaner. Corporate records, contracts, employment files, compliance policies, leases, payer documentation, and licensing materials should be reviewed before a buyer starts asking for them. A practice that is organized is easier to value, easier to diligence, and easier to transfer.

For buyers, diligence is not just about confirming revenue. It is about understanding whether that revenue can continue after closing. That requires looking at the business through a healthcare regulatory lens, not only a financial one.

The best healthcare transactions are planned before they are negotiated. In a regulated market, the legal structure of the deal can be just as important as the business opportunity behind it.